What is the best therapy for a young patient with relapsed/refractory CLL?
What is the best therapy for a young patient with relapsed or refractory chronic lymphocytic leukemia (CLL)? Here, Jacqueline Barrientos, MD, of Feinstein Institute for Medical Research, Manhasset, NY, answers this question, highlighting that one size does not fit all. She discusses issues surrounding the use of chemotherapy for patients and suggests alternative treatments for patients, which include ibrutinib and participating in clinical trials. Dr Barrientos continues to explain the benefits and issues surrounding the use of other novel drugs for patients. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Related videos
From the MD Anderson Cancer Center: A chronic lymphoblastic leukemia (CLL) patient's video diary: Endurance
Harley Hudson
1:49
Encouraging patients to ask about clinical trials
Simon Rule
1:06
Promising treatments are coming: a message to lymphoma and CLL patients
George Follows
1:13
The role of the Patvocates Network in promoting patient advocacy
Jan Geissler
2:10
MPN treatment: traditional, new and upcoming drug insights
Tiziano Barbui
